Cite
Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
MLA
Wang, Yanfang, et al. “Blockade of PLD1 Potentiates the Antitumor Effects of Bortezomib in Multiple Myeloma Cells by Inhibiting the MTOR/NF-ΚB Signal Pathway.” Hematology, vol. 25, no. 1, Dec. 2020, pp. 424–32. EBSCOhost, https://doi.org/10.1080/16078454.2020.1845501.
APA
Wang, Y., Dong, F., Wan, W., Zhang, Z., Wang, J., Wang, H., & Ke, X. (2020). Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway. Hematology, 25(1), 424–432. https://doi.org/10.1080/16078454.2020.1845501
Chicago
Wang, Yanfang, Fei Dong, Wei Wan, Zhenhao Zhang, Jing Wang, Hua Wang, and Xiaoyan Ke. 2020. “Blockade of PLD1 Potentiates the Antitumor Effects of Bortezomib in Multiple Myeloma Cells by Inhibiting the MTOR/NF-ΚB Signal Pathway.” Hematology 25 (1): 424–32. doi:10.1080/16078454.2020.1845501.